Publication & Citation Trends
Most Cited Works
Publications
167 total
Colon Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology PDF
Cited by 266
OpenAlex
Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group
Cited by 274
OpenAlex
Rectal Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology PDF
Cited by 787
OpenAlex
A Phase II Randomized, Double-Blind, Placebo-Controlled Study of Simtuzumab or Placebo in Combination with Gemcitabine for the First-Line Treatment of Pancreatic Adenocarcinoma PDF
Cited by 171
OpenAlex
Phase II Pilot Study of Vemurafenib in Patients With Metastatic <i>BRAF</i> -Mutated Colorectal Cancer PDF
Cited by 687
OpenAlex
Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2–Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC—A Randomized Phase III Trial PDF
Cited by 615
OpenAlex
The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers
Cited by 1,726
OpenAlex
Research Topics
Colorectal Cancer Treatments and Studies
(83)
Gastric Cancer Management and Outcomes
(34)
CAR-T cell therapy research
(33)
Cancer Treatment and Pharmacology
(28)
Lung Cancer Treatments and Mutations
(25)
Frequent Co-Authors
Affiliations
Northwestern University
Ontario Institute for Cancer Research
Santa Monica College
Novartis (Switzerland)
Fox Chase Cancer Center